New type 2 diabetes drug helps lower blood sugar: study
But, FDA wants questions about the drug's long-term safety answered before approval
(HealthDay) -- A new type of medication for type 2 diabetes helps to lower blood sugar levels when used in concert with insulin and other diabetes drugs, new research suggests.
The medicine is called dapagliflozin, and average blood sugar levels were lower in those taking the drug compared to those taking a placebo; both groups in the trial also took insulin and other diabetes medications. Daily insulin doses went down for those on the drug, and body weight dropped slightly.
"This study looked at the effects of dapagliflozin treatment in people with type 2 diabetes with high blood sugars despite insulin treatment, and found it was effective at reducing blood sugar, body weight and blood pressure," said study author Dr. John Wilding, head of the department of obesity and endocrinology at the University Hospital Aintree in Liverpool, England.
"Possible disadvantages include a slightly higher risk of urine infections and genital fungal infections, although most of these responded well to standard treatment," he added.
Results of the study are published in the March 20 issue of the Annals of Internal Medicine. The study was funded by AstraZeneca and Bristol-Meyers Squibb, two pharmaceutical companies who are collaborating in the development of dapagliflozin.
Type 2 diabetes affects the way your body metabolizes sugar. In type 2 diabetes, the body either doesn't use the hormone insulin effectively or it doesn't make enough insulin, according to the U.S. National Library of Medicine. Insulin allows the body's cells to convert sugar from food into fuel. If it isn't used well or there's not enough insulin, blood sugar levels will rise. High blood sugar levels can cause a number of serious health consequences, including damage to the eyes, kidneys and blood vessels.
In some cases, type 2 diabetes can be controlled with lifestyle changes, such as losing weight and exercising regularly. However, most people need medications to control their blood sugar levels, and many people need a combination of medications to lower their blood sugar.
Dapagliflozin is from a new class of type 2 diabetes medications that work by blocking the ability of the kidneys to hold sugar. This causes the kidneys to release sugar as waste in the urine.
Numerous clinical trials have found dapagliflozin to be effective at lowering blood sugar levels. Despite this beneficial effect, the U.S. Food and Drug Administration recently decided not to approve dapagliflozin until more information is available about its possible long-term side effects. The most significant concern cited by the FDA was a potential increase in the rates of bladder and breast cancer in people taking the drug.
Although the current trial wasn't long enough to look for longer-term outcomes, such as cancer, Wilding said that the slight increase in bladder and breast cancer was likely a chance finding. But, he said, because there is concern, it's important to continue surveillance for these cancers in future trials.
The current study was designed to see how the drug would work in combination with insulin and other type 2 diabetes medications.
The researchers enrolled just over 800 people with type 2 diabetes who were already taking insulin to control their blood sugar levels. In addition, the study volunteers could be taking up to two more blood sugar-lowering medications.
Study participants were randomly assigned to one of four treatment groups. They received either a placebo, or one of three doses of dapagliflozin (2.5, 5 or 10 milligrams) daily.
After 24 weeks of treatment, people in the dapagliflozin group lowered their average hemoglobin A1C level between 0.79 percent to 0.96 percent compared with a 0.39 percent reduction in those on placebo. Hemoglobin A1C is about a three-month average blood sugar level. People with diabetes are advised to keep their levels below 7 percent.
Insulin use also dropped for people taking the medication, suggesting more effective blood sugar control. And, body weight decreased between 2 pounds and 3.5 pounds for those taking the medication. Weight increased by almost 1 pound for those on placebo, according to the study.
In addition, the researchers found that both systolic and diastolic blood pressure levels went down more for those on the drug compared to those on placebo.
"In this study, dapagliflozin seemed to improve glucose control and lower the need for insulin, as well as cause some weight loss," said Dr. Sue Kirkman, senior vice president of medical affairs and community information of the American Diabetes Association.
"This is an interesting study on a new medication that's under development. It has a novel mechanism of action, but there have been some ongoing concerns about the safety of this class of medications, and none has been approved by the FDA yet," she noted.
More information: Learn more about type 2 diabetes and currently approved treatments from the American Diabetes Association.
Copyright © 2012 HealthDay. All rights reserved.
- FDA questions safety of experimental diabetes drug Jul 15, 2011 | not rated yet | 0
- Brain important in lowering blood sugar Jan 11, 2006 | not rated yet | 0
- FDA approves new diabetes treatment Oct 17, 2006 | not rated yet | 0
- Mothers' high blood sugar in pregnancy is linked to children's reduced insulin sensitivity Jun 22, 2010 | not rated yet | 0
- Some patients may not need insulin for long-term control of type 2 diabetes Jun 15, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Assumptions of Griffith's fracture theory
5 hours ago Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
Current leading voltage or vice versa concept
7 hours ago Hello, I was wondering if there is a conceptual explanation for when current leads voltage or vice versa for capacitors or inductors with AC...
Angular Frequency of AC voltage
10 hours ago Hello, I am wondering, what is the physical interpretation of the angular frequency of AC voltage? I don't see the physicality of what the angle...
Modeling Rigid Body - Unsure about Euler angles and angular velocity
10 hours ago I'm modeling a single 3D rigid body in preparation for some more complicated modeling in order to gain a better understanding of Euler angles, the...
Function for a bullet's path
12 hours ago I've been mulling this over all weekend, and I've decided to get some help on this. The problem is writing a function to describe a bullet's path....
Elementary questions relating to Newton's laws of motion
13 hours ago i) If a wall breaks when it gets hit by a cannonball, did the wall exert an equal and opposite force on the cannonball? ii) Would the force...
- More from Physics Forums - Classical Physics
More news stories
Study shows that women who smoke during pregnancy increase the risk of both obesity and gestational diabetes in their da
Women who smoke during pregnancy increase the risk of both obesity and gestational diabetes, in their daughters, concludes research published in Diabetologia, the journal of the European Association for the Study of Diabet ...
Diabetes 13 hours ago | not rated yet | 0
The number of young people diagnosed with type 2 diabetes has seen the sharpest rise over the last twenty years compared to a background of a general increase across the board, new University research has ...
Diabetes 23 hours ago | not rated yet | 0
(Medical Xpress)—Flinders University researchers are breaking new ground in a decade-long journey to pinpoint the function of two closely related proteins.
Diabetes May 20, 2013 | 5 / 5 (2) | 0 |
(HealthDay)—Moderate aerobic exercise prevents fructose-induced hypertriglyceridemia in healthy males, according to a study published online May 14 in Diabetes.
Diabetes May 17, 2013 | 5 / 5 (1) | 0 |
A DNA variant near a digestive enzyme does not only affect risk of developing diabetes but also affects the response to treatment, an international consortium of researchers including the University of Dundee has found.
Diabetes May 17, 2013 | not rated yet | 0 |
(HealthDay)—Injections of a sugar solution appear to help relieve knee pain and stiffness related to osteoarthritis, a new study suggests.
26 minutes ago | not rated yet | 0 |
(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...
35 minutes ago | not rated yet | 0 |
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...
30 minutes ago | not rated yet | 0 |
(HealthDay)—Obese and overweight men and women who suffer from heartburn often report relief when they lose weight, a new study shows.
16 minutes ago | not rated yet | 0 |
(HealthDay)—When it comes to the care of your children's teeth, dentists aren't the only experts who can help.
36 minutes ago | not rated yet | 0
(HealthDay)—For patients with acute respiratory distress syndrome (ARDS), prolonged prone positioning during mechanical ventilation is associated with significantly reduced mortality at 28 and 90 days, ...
56 minutes ago | not rated yet | 0